Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CH-AM-1
- Development stage
- Preclinical
- Lead developer
- Cinnabaris Biopharma
- Modality
- Peptides
- Administration
- Subcutaneous
01
Overview
CH-AM-1 is a selective, long-acting amylin receptor agonist (AMYRA) being developed for the treatment of obesity. Developed by Cinnabaris Biopharma, the peptide is designed to potently activate the amylin 1 receptor (AMY1R) while exhibiting significantly reduced activity at the calcitonin receptor (CTR) and amylin 3 receptor (AMY3R) compared to first-generation agonists like cagrilintide. This selectivity profile is intended to enhance weight loss efficacy and improve gastrointestinal tolerability. Preclinical data in cynomolgus monkeys indicate a prolonged half-life that may support once-monthly subcutaneous dosing in clinical settings.
02
Targets
AMY (Pancreatic alpha-amylase)
Beyond the preview
Go deeper on CH-AM-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CH-AM-1.